NurExone Biologic Inc. (TSXV: NRX)

NurExone Biologic Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep 29, 2024	Dec 30, 2023	Dec 30, 2022	Dec 30, 2021
Cash & Equivalents	2.52	0.54	2.46	2.21
Cash & Short-Term Investments	2.52	0.54	2.46	2.21
Cash Growth	120.73%	-78.03%	11.25%	-
Other Receivables	0.26	0.1	0.05	0.52
Receivables	0.26	0.1	0.05	0.52
Prepaid Expenses	-	0.11	0.12	0.09
Restricted Cash	-	1.2	-	-
Other Current Assets	0.04	0.03	0.05	0.02
Total Current Assets	2.82	1.98	2.69	2.84
Property, Plant & Equipment	0.79	0.19	0.1	-
Total Assets	3.61	2.17	2.79	2.84
Accrued Expenses	0.17	0.55	0.46	0.18
Short-Term Debt	-	1.2	-	1.04
Other Current Liabilities	0.26	0.16	0.15	0.41
Total Current Liabilities	0.44	1.91	0.6	1.63
Long-Term Leases	0.03	0	0.02	-
Other Long-Term Liabilities	0.22	0.07	0.08	0.03
Total Liabilities	0.69	1.98	0.7	1.66
Additional Paid-In Capital	17.78	12.16	11.25	3.26
Retained Earnings	-17.55	-14.06	-10.42	-2.25
Comprehensive Income & Other	2.7	2.08	1.26	0.17
Shareholders' Equity	2.93	0.19	2.1	1.18
Total Liabilities & Equity	3.61	2.17	2.79	2.84
Total Debt	0.03	1.2	0.02	1.04
Net Cash (Debt)	2.49	-0.66	2.44	1.17
Net Cash Growth	118.60%	-	108.63%	-
Net Cash Per Share	0.04	-0.01	0.06	0.07
Filing Date Shares Outstanding	70.89	65.81	42.86	34.47
Total Common Shares Outstanding	70.52	48.25	42.86	34.47
Working Capital	2.39	0.07	2.09	1.21
Book Value Per Share	0.04	0.00	0.05	0.03
Tangible Book Value	2.93	0.19	2.1	1.18
Tangible Book Value Per Share	0.04	0.00	0.05	0.03
Machinery	-	0.17	0.05	-

Source: S&P Capital IQ. Standard template. Financial Sources.